Acura Pharmaceuticals Inc., a pharmaceutical firm currently developing and manufacturing drugs to address medication misuse, made an announcement recently of entering into a settlement deal with Sandoz Inc. This is to settle a patent infringement lawsuit made against Sandoz in the Delaware U.S. District Court.
In the filed lawsuit, Acura indicated that the Aversion (R) oxycodone drug, a generic version of the company, led Sandoz to seek for approval of the product in the U.S. market in pursuant of the ANDA (Abbreviated New Drug Application) filing with the FDA (Food and Drug Administration) infringes a patent currently owned by Acura.
Based on the Sandor Settlement Agreement, Sandoz may be allowed to release the generic Aversion (R) oxycodone drug in the country via a non-exclusive grant from Acura to Sandoz. This would trigger 180 days following the first sale of the product in the United States.
The agreement offers a complete settlement of all claims included in the lawsuit against Sandoz.
Comments